CORDIS
EU research results

CORDIS

English EN
Deciphering the fungus-host-microbiota interplay to improve the management of fungal infections

Deciphering the fungus-host-microbiota interplay to improve the management of fungal infections

Objective

Fungal infections have a major impact on human health, infecting about 2 billion people and killing more people each year than malaria or breast cancer. In particular, Candida species impose a high clinical and economic burden upon the European population. They frequently cause fatal hospital-acquired bloodstream infections. They also cause oral thrush and vaginitis. Most women have suffered an episode of vulvovaginal candidiasis, with ~8% enduring recurrent infections. The initiation and severity of a Candida infection depends on an intricate interplay between the infecting fungal strain and the individual’s immune status and microbiota, all of which can display significant variability. Therefore, for the first time, FunHoMic integrates experts in fungal pathogenesis, immunology, microbial ecology and ‘omics technologies to train 13 Early Stage Researchers (ESRs) who will define and exploit this Fungal-Host-Microbiota interplay to identify novel biomarkers (fungal or host genetic polymorphisms, microbiota profiles, metabolites or immune markers) for the stratification of a patient’s risk of serious fungal infection. This will pave the way for precision medicine in patient management through preventive or therapeutic interventions using antifungals, immune modulators or Live Biotherapeutic Products (LBPs). FunHoMic ESRs will gain broad interdisciplinary skills plus a translational mindset through our integrated, inter-sectoral training program. This will allow Europe to remain at the forefront of translational research in the field of medical mycology. To achieve this vision FunHoMic unites academic partners from France, Germany, The Netherlands, Switzerland, Spain and UK, a French Technology Research Institute with cutting-edge ‘omics technology platforms and three SMEs from The Netherlands, Belgium and France that bring unrivalled organ-on-chip and gastro-intestinal tract simulation technologies and expertise in the development and exploitation of innovative LBPs.

Coordinator

INSTITUT PASTEUR

Address

Rue Du Docteur Roux 25-28
75724 Paris Cedex 15

France

Activity type

Research Organisations

EU Contribution

€ 549 604,08

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

LEIBNIZ-INSTITUT FUR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE EV HANS-KNOLL-ISTITUT

Germany

EU Contribution

€ 505 576,80

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 265 619,88

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 281 276,64

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

Spain

EU Contribution

€ 250 904,88

THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

United Kingdom

EU Contribution

€ 606 345,12

BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE

France

EU Contribution

€ 274 802,04

MIMETAS BV

Netherlands

EU Contribution

€ 265 619,88

PRODIGEST

Belgium

EU Contribution

€ 256 320

BIOSE

France

EU Contribution

€ 274 802,04

Partners (8)

Sort alphabetically

Expand all

UNIVERSITE CLERMONT AUVERGNE

UNIVERSITEIT GENT

UNIVERSITEIT LEIDEN

UNIVERSITE PARIS DESCARTES

UNIVERSITAT AUTONOMA DE BARCELONA

FRIEDRICH-SCHILLER-UNIVERSITAT JENA

UNIVERSITE PARIS DIDEROT - PARIS 7

EVOTEC (UK) LIMITED

Project information

Grant agreement ID: 812969

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2022

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 530 871,36

  • EU contribution

    € 3 530 871,36

Coordinated by:

INSTITUT PASTEUR

France